Heartflow, Inc. Common Stock Q2 2026 Earnings Recap

HeartFlow’s Q2 revenue growth and product utilization notably exceeded expectations, driving a 41% surge in the stock. Accelerating commercial adoption across both Plaque and FFRCT segments underpinned a meaningful upward revision in full-year guidance.

Key Takeaways

• Q2 revenue reached $64.1 million, up 48% year-over-year, marking the fastest growth in eight quarters, with U.S. revenue up 51%.
• Full-year 2026 revenue guidance raised to $246 million–$250 million, a 40%–42% increase year-over-year; Plaque revenue guidance increased to $29 million–$31 million.
• Non-GAAP gross margin guidance lifted to ~82%, benefiting from AI-driven efficiency, volume leverage, and higher Plaque revenue mix; maintaining mid-term target of 85%.
• New account additions and physician utilization of both Plaque and FFRCT remained robust; the 340 accounts added in 2025 continue ramping in line with expectations.
• Innovation pipeline progressing with launch of Plaque Staging and continued rollout of PCI Navigator, expected to support adoption into 2027.